产品
编 号：F748618
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 2066544-85-0
产品详情
生物活性：
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity.
体内研究：
Orilanolimab (20mg/kg；静脉注射) 显著降低小鼠模型中HuLys11的血浆浓度。Orilanolimab (10-100 mg/kg；静脉注射；每5周一次) 导致IgG食蟹猴总循环水平的剂量依赖性和特异性降低。
体外研究：
Orilanolimab (10nM、50nM和100nM；48小时) 抑制 B2MTG/TGFCGRTTG/TGFcgrt-/- 小鼠的 CD11c＜sup＞+Orilanolimab 相关抗体:
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity.
体内研究：
Orilanolimab (20mg/kg；静脉注射) 显著降低小鼠模型中HuLys11的血浆浓度。Orilanolimab (10-100 mg/kg；静脉注射；每5周一次) 导致IgG食蟹猴总循环水平的剂量依赖性和特异性降低。
体外研究：
Orilanolimab (10nM、50nM和100nM；48小时) 抑制 B2MTG/TGFCGRTTG/TGFcgrt-/- 小鼠的 CD11c＜sup＞+Orilanolimab 相关抗体:
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备